-
1دورية أكاديمية
المؤلفون: Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
المصدر: Biomarker Research, Vol 10, Iss 1, Pp 1-20 (2022)
مصطلحات موضوعية: HER2-targeted therapy, Gastric cancer, Gastric/gastroesophageal junction adenocarcinoma, Monoclonal antibody, Bispecific antibody, Antibody–drug conjugates, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
Relation: https://doaj.org/toc/2050-7771
-
2دورية أكاديمية
المؤلفون: Li, WeilingAff1, Aff2, Zhang, Xiaoling, Du, Yunyi, Zhang, YingAff1, Aff2, Lu, Jing, Hu, Wenqing, Zhao, JunAff1, IDs4036402200416x_cor7
المصدر: Biomarker Research. 10(1)
-
3دورية أكاديمية
المؤلفون: Haiping Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, Xin Xu, Ning Li, Cheng Xiao, Huan Wang, Lisong Teng, Hui Zhou, Shuyan Wang, Donglei Zhu, Bo Peng, Lin Shen, Nong Xu
المصدر: BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
مصطلحات موضوعية: Sintilimab, Capecitabine, Oxaliplatin, Gastric/gastroesophageal junction adenocarcinoma, Tumor mutation burden, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
4دورية أكاديمية
المؤلفون: Caiyun Nie, Huifang Lv, Yingjun Liu, Beibei Chen, Weifeng Xu, Jianzheng Wang, Xiaobing Chen
المصدر: Frontiers in Oncology, Vol 11 (2021)
مصطلحات موضوعية: gastric/gastroesophageal junction adenocarcinoma, sintilimab, immunotherapy, efficacy, Lauren classification, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
المؤلفون: Jiang, Haiping, Zheng, Yulong, Qian, Jiong, Mao, Chenyu, Xu, Xin, Li, Ning, Xiao, Cheng, Wang, Huan, Teng, Lisong, Zhou, Hui, Wang, Shuyan, Zhu, Donglei, Peng, Bo, Shen, Lin, Xu, NongAff1
المصدر: BMC Cancer. 20(1)
-
7دورية أكاديمية
المؤلفون: Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik-Tobias Arkenau, Jennifer Cultrera, Rafael Santana-Davila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, Gu Mi, Ling Gao, Samuel Clark McNeely, Joana M. Oliveira, David Ferry, Roy S. Herbst, Charles S. Fuchs
المصدر: Cancers, Vol 12, Iss 10, p 2985 (2020)
مصطلحات موضوعية: gastric/gastroesophageal junction adenocarcinoma, pembrolizumab, phase 1b, ramucirumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9
المؤلفون: Zev A. Wainberg, Keun-Wook Lee, Inho Kim, Anwaar Saeed, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Daniel V.T. Catenacci, Raquel Guardeño, Christophe Borg, Siddhartha Mitra, Erika Hitre, Jin Li, Anghel Adrian Udrea, Yoon-Koo Kang, Kensei Yamaguchi, Yingsi Yang, Sang Cheul Oh, Shukui Qin, Peter C. Enzinger, Haci Mehmet Turk
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Placebo, Monoclonal antibody, Gastroenterology, Double blind, Oncology, A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 [Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT], Internal medicine, Fibroblast Growth Factor Receptor 2b, Medicine, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84cd51b695b646eaa8b082749dbaa24
http://hdl.handle.net/20.500.12645/29666 -
10
المؤلفون: Andres O. Soriano, Nicolas Penel, Hendrik-Tobias Arkenau, Lars Zender, Ling Gao, Rafael Santana-Davila, Joana M Oliveira, Roy S. Herbst, Jennifer L. Cultrera, Ian Chau, Samuel McNeely, Johanna C. Bendell, Christophe Le Tourneau, Emiliano Calvo, Charles S. Fuchs, David Ferry, Gu Mi
المصدر: Cancers, Vol 12, Iss 2985, p 2985 (2020)
Cancers
Volume 12
Issue 10مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, ramucirumab, Pembrolizumab, lcsh:RC254-282, Article, Ramucirumab, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, 030212 general & internal medicine, phase 1b, Adverse effect, Antitumor activity, business.industry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, gastric/gastroesophageal junction adenocarcinoma, Tolerability, 030220 oncology & carcinogenesis, Adenocarcinoma, pembrolizumab, business
وصف الملف: application/pdf